



Patent Application no. 09/972,402  
Attorney's Docket No. 3053-034

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Kenneth C. Cundy. et al.

Application No.: 09/972,402

Filed: October 5, 2001

For: Compounds for Sustained Release of  
Orally Delivered Drugs

Group Art Unit: 1619

Examiner: Unassigned

RECEIVED  
FEB 01 2002  
TECH CENTER 1600/2900  
#5

**INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of IDS as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of IDS as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$\_\_\_\_\_ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300  
Date: January 29, 2002

By:   
Anthony T. Cascio  
Registration No. 29,904



Patent Application no. 09/972,402  
Attorney's Docket No. 033033-034

RECEIVED  
FEB 01 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Patent Application of )  
Kenneth C. Cundy. et al. ) Group Art Unit: 1619  
Application No.: 09/972,402 ) Examiner: Unassigned  
Filed: October 5, 2001 )  
For: Compounds for Sustained Release of )  
Orally Delivered Drugs )

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed:

**Articles:**

- Gotoh, et al., *J. Pharmacol., Exp. Ther.*, 2000, 292, pp. 433-439
- Iantomasi, et al., *Biochim. Biophys. Acta*, 1997, 1330, pp. 274-283
- Kouzuki, et al., *J. Pharmacol. Exp. Ther.*, 1999, 288, pp. 627-634
- Salach, et al., *Pharm. Res.*, 1994, 11, pp. 1429-1434
- Suzuki, et al., *Sem. Liver Disease*, 2000, 20, pp. 251-263
- Tokui, et al., *Pharm. Res.*, 1999, 16, pp. 904-908
- Yamazaki, et al., *Drug Metab. Dispos.*, 1997, 15, pp. 1123-1129

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:



Anthony T. Cascio  
Registration No. 29,904

Burns, Doane, Swecker & Mathis  
P.O. Box 1404  
Arlington, VA 22313  
Firm Phone: (650) 622-2300

Date: January 29, 2002

FIELD(IDS DATE)